This trial is evaluating whether PF-06651600 will improve 1 primary outcome and 28 secondary outcomes in patients with Alopecia Areata. Measurement will happen over the course of Vaccine sub-study Day 1 and Month 1.
This trial requires 1050 total participants across 2 different treatment groups
This trial involves 2 different treatments. PF-06651600 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"There are many treatments for alopecia that can decrease, halt or reverse the signs and symptoms. Treatments such as hair transplants can be used to restore hair to a healthier appearance." - Anonymous Online Contributor
"Although there is no cure, the use of products such as sulfasalazine, minoxidil or finasteride may decrease hair loss as a result of alopecia. Finasteride can help some patients with peribulbar skin tags, but not alopecia." - Anonymous Online Contributor
"Around 30.2 millions suffer from female pattern hair loss in the United States. According to the 2010 National Health Interview Survey, around 21.7 million individuals are affected by female pattern hair loss in the United States." - Anonymous Online Contributor
"Alopecia is a condition that involves the permanent or temporary loss of hair from almost the whole body. It affects about one-third of men and the most commonly occurring is male pattern baldness. Alopecia affects about 18% of men. A survey of 3,731 men between the ages of 20 and 79 from four different counties revealed that the prevalence of alopecia is 7.3% and about half of the cases are male." - Anonymous Online Contributor
"Alopecia areata is characterized by the baldness of the scalp to the level of the eyebrows, which is associated with the loss of hair and skin on the sides of the head. Patients are usually asymptomatic other than the baldness which gives a sign that the condition is severe as the more scalp hair is lost, the less likely the patient will be symptomatic and less severe the alopecia.\n" - Anonymous Online Contributor
"Alopecia is caused by different genetic, neurological and endocrine conditions, and some infections. To improve hair growth, it is important to find the cause. All patients with hair loss need to exclude other diseases or drug side effects, like hormonal imbalance, and to be monitored for hair loss." - Anonymous Online Contributor
"This was a review of recent studies showing the potentiality of some compounds in growing the alopecia hair in patients with severe hair loss. Further studies need to be conducted, using this review as an impetus, but it is already important to know that this could be a potential treatment option." - Anonymous Online Contributor
"This specialised journal, Moll Folligo, focuses on research into the cause, prevention, medical and cosmetic treatments for hair disorders. There are still many unanswered questions in the field of hair loss. It is not known whether there can be regenerating cells in the hair follicle." - Anonymous Online Contributor
"The adverse reactions reported in the studies for PF-06651600 were more similar to those reported in placebo-treated patients, but were generally mild and transient in most cases. A subset of patients experienced a worsening of hair loss after starting PF-06651600 treatment; patients with preexisting hair loss may be at increased risk for the development of such a worsening." - Anonymous Online Contributor
"Pf-0451600 showed strong antifibrotic effects in a subset of patients with scarring alopecia, although clinical effect is dependent on dose and duration. Further randomized, double-blinded, placebo-controlled trials are mandatory to establish safety and efficacy of this agent." - Anonymous Online Contributor
"At present, one of the most effective medicines to alleviate the symptoms of androgenic alopecia is finasteride. The most recent development in pf-06651600 is a new prodrug formulation, PF-06651600AA, which contains the same dose level as that of finasteride. Moreover, PF-06651600AA can be administrated via oral, intramuscular or transdermal routes, which can obviously improve the therapeutic effect. And PF-06651600AA has been shown to be effective in a mouse model, which may indicate that PF-06651600AA can be an effective and safe therapy for androgenic alopecia." - Anonymous Online Contributor
"Alopecia is a remarkably complex genetic trait. Genetic factors play a major role in the aetiology of this condition. The inheritance in families with the same family history can be strongly suggestive of genetic susceptibility." - Anonymous Online Contributor